Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC
- 31 March 2004
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 58 (3) , 991-1002
- https://doi.org/10.1016/j.ijrobp.2003.09.099
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancerExpert Opinion on Biological Therapy, 2001
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- ZD1839 (???Iressa???)*,??? as an Anticancer AgentDrugs, 2000
- Treatment Strategies for Metastatic Non–Small-Cell Lung CancerClinical Lung Cancer, 1999
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1999
- 24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)Lung Cancer, 1997
- Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtypeEuropean Journal Of Cancer, 1995